Appetite, Obesity, Metabolism, and Malignancy: Do Incretin-Mimetic Drugs Reduce Cancer Risk?

Area of Science:

• Oncology
• Endocrinology
• Metabolic Diseases

Background:

• Obesity is a significant risk factor for numerous adult cancers, second only to tobacco.
• Intentional weight loss's impact on cancer risk reduction remains an area of uncertainty.
• Bariatric surgery demonstrates that substantial weight loss (20-30%) can lower obesity-related cancer risk over a decade.

Purpose of the Study:

• To review current evidence on weight loss and cancer risk.
• To evaluate the potential of incretin-mimetic drugs, like GLP-1 RAs, for cancer prevention.
• To assess the feasibility of conducting cancer prevention trials with these agents.

Main Methods:

• Review of existing data on bariatric surgery and cancer outcomes.
• Analysis of randomized trial data for GLP-1 RAs regarding weight loss.
• Assessment of the rationale and feasibility for incretin-mimetic cancer prevention trials.

Main Results:

• Bariatric surgery shows promise but isn't scalable for population-level cancer prevention.
• GLP-1 RAs induce significant weight loss (approx. 15%) in obese individuals, with drugs like semaglutide and tirzepatide leading the field.
• A strong rationale exists for exploring GLP-1 RAs in cancer prevention, though trial feasibility is a concern.

Conclusions:

• While bariatric surgery offers insights, GLP-1 RAs represent a more accessible approach for obesity management and potential cancer risk reduction.
• Further research and clinical trials are warranted to confirm the cancer preventive potential of incretin-mimetic drugs.
• The development of new GLP-1 RAs necessitates ongoing evaluation of their role in managing obesity-related diseases, including cancer.